Esperion to Report Third Quarter 2020 Financial Results November 2, 2020

Rhea-AI Summary

Esperion (NASDAQ: ESPR) is set to announce its third quarter 2020 financial results on November 2, 2020, after market close. Following the announcement, management will hold a conference call at 4:30 p.m. ET to discuss the outcomes and business developments. The call can be accessed by dialing the specified numbers, and a live audio webcast will be available on their investor website. Esperion is focused on developing oral LDL-C lowering medications to address cardiovascular disease, which affects a significant portion of the U.S. population.

Positive

• Focus on developing oral LDL-C lowering medicines to tackle cardiovascular disease.
• Management's commitment to significantly impact global health through innovative treatments.

Negative

• Potential risks related to clinical development and commercialization plans.
• Dependence on existing cash resources, which may deplete faster than expected.

ANN ARBOR, Mich., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report third quarter 2020 financial results after the close of the U.S. financial markets on Monday, November 2, 2020.

Following the release, company management will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and business progress. The call can be accessed by dialing (877) 831-3840 (domestic) or (253) 237-1184 (international) five minutes prior to the start of the call and providing the access code 9377299.

A live audio webcast can be accessed on the investor and media section of the Esperion website at investor.esperion.com. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.

Esperion Therapeutics

Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make a substantial impact on reducing global cardiovascular disease, the leading cause of death around the world. For more information, please visit www.esperion.com and follow us on Twitter at www.twitter.com/EsperionInc.

Esperion Therapeutics’ Commitment to Patients with Hyperlipidemia

High levels of LDL-C can lead to a build-up of fat and cholesterol in and on artery walls (known as atherosclerosis), potentially leading to cardiovascular events, including heart attack and stroke. In the U.S., 96 million people, or more than 37 percent of the adult population, have elevated LDL-C. There are approximately 18 million people in the U.S. living with elevated levels of LDL-C despite taking maximally tolerated lipid-modifying therapy — including individuals considered statin averse — leaving them at high risk for cardiovascular events¹. In the United States, more than 50 percent of atherosclerotic cardiovascular disease (ASCVD) patients and heterozygous familial hypercholesterolemia (HeFH) patients who are not able to reach their guideline recommended LDL-C levels with statins alone need less than a 40 percent reduction to reach their LDL-C threshold goal².

Esperion's mission as the Lipid Management Company is to deliver oral, once-daily medicines that complement existing oral drugs to provide the additional LDL-C lowering that these patients need.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding Esperion's expectations for the market for medicines to lower LDL-C. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion's actual results to differ significantly from those projected, including, without limitation, delays or failures in Esperion’s clinical development and commercialization plans, or approval of expanded indications, that existing cash resources may be used more quickly than anticipated, the impact of COVID-19 on our business, clinical activities and commercial development plans, and the risks detailed in Esperion's filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

References
^{(1)  Esperion market research on file: research project interviewing 350 physicians. Esperion Therapeutics, Inc. Sept-Oct 2018.
(2)  Data on file: analysis of NHANES database. Esperion Therapeutics, Inc. 2018.}

Investor Contact:
Kaitlyn Brosco
Esperion
investorrelations@esperion.com

FAQ

When will Esperion report its Q3 2020 financial results?

Esperion will report its Q3 2020 financial results on November 2, 2020.

What time is the conference call following the financial results announcement?

The conference call will take place at 4:30 p.m. ET on November 2, 2020.

How can I access the live audio webcast for Esperion's financial results?

The live audio webcast can be accessed on the investor section of Esperion's website.

What is Esperion's main focus in terms of product development?

Esperion is dedicated to developing oral medicines that lower LDL-C levels to reduce cardiovascular disease risks.